Tumour-derived leukaemia inhibitory factor is a major driver of cancer cachexia and morbidity in C26 tumour-bearing mice.

ABSTRACT:

Background

Cancer cachexia is a metabolic wasting syndrome that is strongly associated with a poor prognosis. The initiating factors causing fat and muscle loss are largely unknown. Previously, we found that leukaemia inhibitory factor (LIF) secreted by C26 colon carcinoma cells was responsible for atrophy in treated myotubes. In the present study, we tested whether C26 tumour-derived LIF is required for cancer cachexia in mice by knockout of Lif in C26 cells.

Methods

A C26 Lif null tumour cell line was made using CRISPR-Cas9. Measurements of cachexia were compared in mice inoculated with C26 vs. C26^Lif-/- tumour cells, and atrophy was compared in myotubes treated with medium from C26 vs. C26^Lif-/- tumour cells. Levels of 25 cytokines/chemokines were co

SUBMITTER: Kandarian SC 

PROVIDER: S-EPMC6240747 | biostudies-literature | 2018 Dec

REPOSITORIES: biostudies-literature